Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Immune Oncology Research Institute
Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Description
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The final diagnosis of BPDCN relies on a compatible immunophenotype. The triple positive CD4+CD56+CD123+ phenotype associated with negativity for lineage-specific markers is a minimum requirement for defining BPDCN. The highly specific marker BDCA2/CD303, as well as other plasmacytoid dendritic cell-associated antigens (e.g. TCL1 and CD2AP), might be of gr…
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-
Locations (20)
- Sylvester Comprehensive Cancer Center, University of MiamiMiami, Florida
- Moffitt Cancer CenterTampa, Florida
- Seattle Children's Cancer and Blood Disorders CenterSeattle, Washington
- Hematology Center named after prof. R. YeolyanYerevan
- University of CalgaryCalgary, Alberta
- Children's Hospital of Eastern Ontario, University of OttawaOttawa, Ontario